Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

March 16, 2023 04:10 PM EDTUpdated 04:24 PM

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Zachary Brennan

Senior Editor

Sanofi today joined with the other two insulin juggernauts in the US to lower the price of its best-selling insulin product, Lantus (insulin glargine), by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

US drugs rely heavily on ingredients made overseas, new report shows

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Three­'s com­pa­ny: Sanofi fol­lows lead of Lil­ly and No­vo, slash­es in­sulin price by 78% and caps out-of-pock­et costs

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs